ASX:CU6Pharmaceuticals
Clarity Pharmaceuticals (ASX:CU6) Is Down 5.2% After PSMA Imaging Trial Hits Primary Endpoint Has The Bull Case Changed?
Clarity Pharmaceuticals recently announced that its Co-PSMA Investigator-Initiated Trial led by St Vincent's Hospital Sydney achieved its primary endpoint, with 64Cu-SAR-bisPSMA detecting a statistically significant higher number of prostate cancer lesions in patients with low PSA compared to the standard-of-care PET/CT imaging.
This outcome highlights the potential for 64Cu-SAR-bisPSMA to improve early detection and staging of prostate cancer, addressing a significant clinical need within...